Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695926 · ClinicalTrials.gov registry record · Early Phase 1
Assessment of [18F]MNI-1054 as a Marker for LSD1
A Early Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT03695926: Completed Early Phase 1 study, sponsored by Invicro.
NCT03695926 is a Early Phase 1 study that has completed, run by Invicro. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695926, a Early Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.
Primary Outcome
Adequacy of the initial scan brain uptake for completion of a retest scan will be based on maximum Standard Uptake value (SUV), where a maximum SUV \> 1.5 will be considered sufficient, possibly sufficient between 1.0 and 1.5, and insufficient below 1.0.
Interventions
- DRUG [18F]MNI-1054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2019-05-02 |
| Phase | Early Phase 1 |
What the finished NCT03695926 record still lists
NCT03695926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-1054 is the first listed.
NCT03695926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03695926 about?
NCT03695926 is a clinical study titled "Assessment of [18F]MNI-1054 as a Marker for LSD1". The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.
What is the current status of trial NCT03695926?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2018-08-09. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT03695926?
The interventions under investigation include: [18F]MNI-1054 (DRUG).
Who is sponsoring clinical trial NCT03695926?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03695926's enrollment target sits among peer trials
4 1922nd of 2000 higher than 53 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI